March 18, 2020 / 10:16 PM / in 13 days

BRIEF-Dicerna Receives Orphan Drug Designation From U.S. FDA For Dcr-A1at For Treatment Of Alpha-1 Antitrypsin Deficiency

March 18 (Reuters) - Dicerna Pharmaceuticals Inc:

* DICERNA RECEIVES ORPHAN DRUG DESIGNATION FROM U.S. FOOD AND DRUG ADMINISTRATION FOR DCR-A1AT FOR TREATMENT OF ALPHA-1 ANTITRYPSIN DEFICIENCY

* DICERNA PHARMACEUTICALS - EXPECTS TO DOSE FIRST PATIENT IN H2 2020 IN PHASE 1/2 TRIAL OF DCR-A1AT Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below